This effort was regarded as submaximal and therefore at the two subsequent exercise visits, Protein Tyrosine Kinase inhibitor subjects were required to perform twice as many squats as they had performed during the screening visit. Outcome Measures The primary outcome measures were assessments of pain and tenderness. Pain was assessed using a Visual Analog Scale (VAS) pain score comprised of four subscales (current

pain, least amount of pain, most amount of pain, and whether pain was interfering with function) each of which was measured on a scale from 0 (no pain) to 10 (worst possible pain). Tenderness was assessed using an algometer (set at level 4) to experimentally induce pain on a predefined point on the patellar tendon five centimeters above the center of the patella. Subjects then ranked their pain perception on a scale from 0 to 10. On day 30, assessments were taken at baseline (pre-exercise), and again at six hours post-exercise. Subjects returned for further assessments 24, 48 and 72 BB-94 mouse hours post-exercise for of each arm of the study. Secondary outcomes included assessments of inflammation, muscle damage,

flexibility, and the amount of energy expended prior to exercise. Blood was drawn on day 30 (pre-exercise), and 6, 24, 48 and 72 hours post exercise. Assays were performed for creatine phosphokinase (CPK), myoglobin, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, Cyclic nucleotide phosphodiesterase and IL-6. Flexibility was measured using standard flexion and extension measures and range of motion (ROM) assessments for both legs. Data on energy expenditure (EE) was collected using the SenseWear ™ armband device. This armband, which has been validated by several studies [15–17], uses a 2-axis accelerometer, a heat flux sensor, a galvanic skin response sensor, a skin temperature sensor and a near-body ambient temperature sensor to capture data. These data, in combination with body weight, height, handedness and smoking status, are used to calculate EE. The armband was placed on the upper arm and worn continuously for the

48 hours prior to exercise in order to assess whether the level of activity prior to exercise impacted any of the primary or secondary outcomes. To determine the safety profile of the product compared with placebo, the following assays were performed on blood drawn at baseline and again at 72 hours post-exercise in each arm of the study: complete blood count (CBC), kidney function, liver function, prothrombin time/partial thromboplastin time (PT/PTT), and urinalysis. Adverse Event monitoring was conducted throughout the study using standardized assessments at each visit. Results Safety Assessment No adverse events were reported during the study period. In addition, no buy Tozasertib clinically significant changes were seen in any of the laboratory safety values (CBC, liver function, kidney function, PT/PTT, and urinalysis) in either group.